Dpp-4 Inhibitors
Dpp-4 Inhibitors - Related Videos
01:23
Dipeptidyl Peptidase 4 Inhibitors
0 Views •
2024
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
06:12
Imaging Dpp Release from a Drosophila Wing Disc
0 Views •
Cited by 2 •
2019
The timing of exposure to ligands may impact their developmental consequences. Here we show how to image release of a Drosophila bone morphogenetic protein (BMP) called Dpp from cells of the wing disc.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
02:57
Evaluating Inhibitor Effects on Pellicle Formation in Bacillus subtilis
0 Views •
2026
Source: Bucher, T., et al. Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors. J. Vis. Exp. (2016)This video demonstrates a pellicle formation assay using Bacillus subtilis to evaluate small-molecule inhibitors that disrupt matrix synthesis and biofilm development, providing a model to screen compounds that selectively inhibit surface-associated growth without affecting free-floating cells.
FAQs
DPP-4 inhibition prolongs incretin signaling by preventing enzymatic degradation of GLP-1 and GIP. After food intake, preserved incretins support insulin secretion when glucose is elevated and suppress glucagon release. This coordinated response improves regulation around meals rather than forcing insulin activity independently of glucose concentration.
The glucose dependence of this pathway explains why DPP-4 inhibitors generally have a low hypoglycemia risk: their effects are linked largely to elevated glucose rather than being constant. The same pharmacologic profile is associated with weight neutrality, making these characteristics relevant when assessing treatment options for type 2 diabetes.
Preserving both GLP-1 and GIP matters because the mechanism is not limited to a single incretin signal. DPP-4 blockade allows these hormones to remain available after meals, supporting glucose-dependent insulin secretion while reducing glucagon release. Pharmacologically, this links the drug effect to coordinated regulation of two named incretin pathways.
Pharmacology studies of DPP-4 inhibitors evaluate more than glucose lowering alone. They examine how each medicine is metabolized, how dosing is selected, and whether other drugs may alter its use through interactions. These dimensions help connect the molecular mechanism with practical prescribing decisions and support appropriate assessment of treatment behavior.
Combination therapy becomes relevant when glycemic control remains inadequate with the current regimen. In that setting, a DPP-4 inhibitor may be studied or used as part of a broader treatment plan rather than viewed in isolation. The rationale is to address persistent glucose dysregulation while retaining attention to dosing, metabolism, and potential drug interactions.
Meal-related glucose changes are central to the pharmacology because GLP-1 and GIP act within the post-meal setting described for these medicines. Preserving incretin activity then supports insulin secretion and reduces glucagon release when glucose rises. This timing helps explain the glucose-dependent profile and the emphasis on postprandial regulation in pharmacology studies.